Abstract CT022: Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study

作者
Saurav Daniel Haldar,Amanda L. Huff,Elizabeth Abou Diwan,Anna K. Ferguson,Carol Judkins,Jiayun Lu,Hao Wang,Hassan Sinan,Christopher J. Thoburn,Katherine M. Bever,Mark M. Yarchoan,Amy Morck Thomas,Julie M. Nauroth,Daniel A. Laheru,Michael Goggins,Elizabeth M. Jaffee,Nilofer Saba Azad,Neeha Zaidi
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:84 (7_Supplement): CT022-CT022 被引量:13
标识
DOI:10.1158/1538-7445.am2024-ct022
摘要

Abstract Background: The development of pancreatic ductal adenocarcinoma (PDAC) from the first driver event takes >10 years, providing a unique window of opportunity for early interception. As a frequent alteration identified in both PDAC and pancreatic premalignancy, mutant KRAS (mKRAS) has emerged as a potential target for immune-based interception strategies in individuals at high risk of developing pancreatic cancer. Methods: This is a single-arm, open-label, second-in-human phase I study of a pooled synthetic long peptide (SLP) vaccine with poly-ICLC adjuvant targeting up to six mKRAS subtypes (G12D, G12R, G12V, G12A, G12C, G13D) in patients with hereditary predisposition to developing PDAC (NCT05013216). Key inclusion: radiographic evidence of a pancreatic abnormality and eligibility under at least one of three high-risk groups based on family history of PDAC and/or germline mutation status. Vaccination schema: mKRAS vaccine given on weeks 1, 3, 5, and 13. Peripheral blood collected at baseline and weeks 5, 13, and 17 for analysis of immunogenicity by IFN-gamma ELISpot. Co-primary endpoints: safety and mKRAS-specific T cell response. Results: At the time of data cutoff (November 15, 2023), 15 out of 20 planned patients were vaccinated on study and evaluable for immunogenicity. All 15 patients achieved a mKRAS-specific T cell response, defined by the maximal fold change in the pooled average IFN-gamma-producing mKRAS-specific T cell density within 17 weeks post-vaccination (median: 12.3, range: 3.1-167). Differential immunogenicity elicited by individual mKRAS epitopes was noted in this cohort. Specifically, the mKRAS G12V peptide induced the highest fold change increase in antigen-specific T cell expansion (median: 32.6, range: 2.9-243) while the mKRAS G12D peptide was the least immunogenic (median: 7.6, range: 0.4-104). Regarding safety, all adverse events were grade 1 or grade 2 in severity per NCI CTCAE v5.0. The most frequent vaccine-related adverse events were injection site reactions (93.8%), fatigue (62.5%), chills (43.8%), and headache (37.5%). No safety signals were observed. Conclusions: For the first time, we demonstrate mKRAS-specific T cell responses induced by vaccination in a cohort of high-risk individuals with inherited predisposition to PDAC. These findings directly serve as proof-of-concept to advance vaccine strategies focused on intercepting the development of pancreatic cancer in high-risk populations. Support: Stand Up To Cancer, Lustgarten Foundation, and NIH/NCI. Citation Format: Saurav D. Haldar, Amanda Huff, Elizabeth Abou Diwan, Anna Ferguson, Carol Judkins, Jiayun Lu, Hao Wang, Hassan Sinan, Christopher Thoburn, Katherine M. Bever, Mark Yarchoan, Amy M. Thomas, Julie M. Nauroth, Daniel A. Laheru, Michael G. Goggins, Elizabeth M. Jaffee, Nilofer S. Azad, Neeha Zaidi. Mutant KRAS peptide-based vaccine in patients at high risk of developing pancreatic cancer: Preliminary analysis from a phase I study [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(7_Suppl):Abstract nr CT022.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
脑洞疼的应助被Miraitowa采纳,获得10
1秒前
1秒前
李健的应助被核桃采纳,获得10
2秒前
2秒前
CodeCraft的应助被年轻的抽屉采纳,获得10
2秒前
Akim的应助被杰里西采纳,获得30
2秒前
顺利毕业发布了新的文献求助10
2秒前
3秒前
SciGPT的应助被孤独听雨的猫采纳,获得10
3秒前
研友_VZG7GZ的应助被阿业采纳,获得10
3秒前
sml发布了新的文献求助10
3秒前
害羞雨南的应助被33采纳,获得30
3秒前
lyc发布了新的文献求助10
3秒前
华仔的应助被织梦采纳,获得10
3秒前
Kaitlyn发布了新的文献求助20
3秒前
星辰大海的应助被zhao采纳,获得10
4秒前
实验狗发布了新的文献求助10
4秒前
zxr完成签到,获得积分10
4秒前
yimin完成签到,获得积分10
4秒前
张伟发布了新的文献求助10
4秒前
花火发布了新的文献求助10
4秒前
4秒前
5秒前
5秒前
洛初完成签到,获得积分10
5秒前
5秒前
5秒前
6秒前
SciGPT的应助被核桃采纳,获得10
6秒前
鳗鱼尔芙完成签到 ,获得积分10
6秒前
希望天下0贩的0的应助被核桃采纳,获得10
6秒前
Orange的应助被核桃采纳,获得10
6秒前
烟花的应助被温暖砖头采纳,获得10
6秒前
思源的应助被核桃采纳,获得10
6秒前
Zhang_Dian发布了新的文献求助10
6秒前
爆米花的应助被核桃采纳,获得10
6秒前
Orange的应助被核桃采纳,获得10
6秒前
思源的应助被WilliamsR1123采纳,获得10
6秒前
coolru的应助被核桃采纳,获得10
6秒前
失眠的念桃完成签到,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124